Page 4 - Simchon Faigler News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Simchon faigler. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Simchon Faigler Today - Breaking & Trending Today

Compugen Ltd. (NASDAQ:CGEN) Expected to Announce Earnings of -$0.13 Per Share

Analysts expect Compugen Ltd. (NASDAQ:CGEN – Get Rating) to announce earnings per share (EPS) of ($0.13) for the current quarter, Zacks reports. Zero analysts have issued estimates for Compugen’s earnings, with the lowest EPS estimate coming in at ($0.15) and the highest estimate coming in at ($0.11). Compugen reported earnings of ($0.12) per share during […] ....

Thomson Reuter , Simchon Faigler , Eli Mintz , Morgan Stanley , Geode Capital Management , Compugen Ltd , Zacks Investment Research , Compugen Company Profile Get Rating , Royal Bank , Get Rating , Investment Research , Capital Management , Street Corp , Company Profile , Amir Natan , Nasdaq Cgen ,

Oppenheimer Comments on Compugen Ltd.'s FY2026 Earnings (NASDAQ:CGEN)

Compugen Ltd. (NASDAQ:CGEN – Get Rating) – Equities research analysts at Oppenheimer issued their FY2026 earnings per share estimates for Compugen in a report released on Friday, February 25th. Oppenheimer analyst M. Breidenbach expects that the biotechnology company will post earnings of ($0.65) per share for the year. Oppenheimer has a “Outperform” rating and a […] ....

Simchon Faigler , Eli Mintz , Goldman Sachs Group Inc , Compugen Ltd , Stifel Financial Corp , Zacks Investment Research , Eagle Rock Investment Company , Antonetti Capital Management , Walleye Trading , Get Rating , Investment Research , Rock Investment Company , Sachs Group , Capital Management , Amir Natan , Nasdaq Cgen , Earnings Estimates , Oppenheimer Holdings Inc ,

Compugen (NASDAQ:CGEN) Given New $14.00 Price Target at Oppenheimer

Compugen (NASDAQ:CGEN – Get Rating) had its target price decreased by Oppenheimer from $17.00 to $14.00 in a research note published on Friday, Analyst Price Targets reports. Oppenheimer currently has an outperform rating on the biotechnology company’s stock. Oppenheimer also issued estimates for Compugen’s FY2026 earnings at ($0.65) EPS. A number of other brokerages have […] ....

Simchon Faigler , Eli Mintz , Compugen Ltd , Zacks Investment Research , Oppenheimer Co , Invesco Ltd , Compugen Company Profile Get Rating , Barclays Plc , Bridgefront Capital , Walleye Trading , Get Rating , Analyst Price Targets , Investment Research , Company Profile , Amir Natan , Nasdaq Cgen , Lower Price Target , Oppenheimer Holdings Inc ,

Compugen (NASDAQ:CGEN) Upgraded to Hold by Zacks Investment Research

Compugen (NASDAQ:CGEN) Upgraded to Hold by Zacks Investment Research
etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.

United States , Simchon Faigler , Eli Mintz , Wedbush Securities Inc , Clearwater Capital Advisors , Compugen Ltd , Zacks Investment Research , Oppenheimer Co , Public Employees Retirement Association Of Colorado , Compugen Company Profile , Bridgefront Capital , Investment Research , Employees Retirement Association , Capital Advisors , Amir Natan ,